Description: Curative Biotechnology, Inc., doing business as Connectyx, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.
Home Page: curativebiotech.com
1825 NW Corporate Boulevard
Boca Raton,
FL
33431
United States
Phone:
561 907 8990
Officers
| Name | Title |
|---|---|
| Mr. Paul M. Michaels | Pres & Exec. Chairman |
| Mr. I. Richard Garr Esq., J.D. | CEO, CFO, Principal Accounting Officer & Gen. Counsel |
| Dr. Barry A. Ginsberg B.A., B.S. | Chief Strategy Officer, Vice Chairman and Member of Scientific & Clinical Advisory Board |
| Mr. Pam Bisikirski | VP of Communications |
| Dr. Ronald Bordens Ph.D. | Exec. VP of Process Product Drug Devel. and Member of Scientific & Clinical Advisory Board |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 158.5303 |
| IPO Date: | 2017-09-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |